曲普瑞林
医学
促黄体激素
促性腺激素释放激素激动剂
促性腺激素释放激素
内科学
内分泌学
骨龄
兴奋剂
性早熟
皮下注射
促卵泡激素
亮丙瑞林
激素
受体
作者
Preamrudee Poomthavorn,Patcharin Khlairit,Pat Mahachoklertwattana
摘要
<i>Background:</i> A test involving 100 μg of intravenous gonadotropin-releasing hormone (GnRH) is a gold standard for confirming the diagnosis of central precocious puberty (CPP). However, intravenous GnRH for testing is commercially limited. <i>Objective:</i> To develop subcutaneous GnRH agonist (GnRH-A) testing and define a peak luteinizing hormone (LH) cutoff value in diagnosing CPP. <i>Methods:</i> A retrospective study of 101 girls with sexual precocity was undertaken. All girls underwent 100 μg subcutaneous GnRH-A (triptorelin) testing. Blood samples before and 30, 60, 90 and 120 min after GnRH-A injection were analyzed for LH and follicle-stimulating hormone levels. Criteria for diagnosing CPP include accelerated height, advanced bone age and pubertal-sized uterus and ovaries. <i>Results:</i> Fifty-five girls were documented as having CPP. The remaining 46 girls were diagnosed with premature thelarche (PT). Peak LH concentration in the CPP group was significantly greater than that of the PT group with a median (range) of 10.0 IU/l (2.93–65.39) and 3.04 IU/l (0.19–8.82), respectively. Peak LH was achieved within 60 min following GnRH-A injection. Peak LH of 6 IU/l provided the most appropriate cutoff level in diagnosing CPP with a sensitivity of 89.1% and a specificity of 91.3%. <i>Conclusion:</i> Subcutaneous GnRH-A can be used as an alternative to confirm the diagnosis of CPP.
科研通智能强力驱动
Strongly Powered by AbleSci AI